According to gene mutation types, tumor driver gene-derived inhibitors (including EGFR inhibitor, ROS1 inhibitor, and ALK inhibitor) have been screened and used for stratifying treatments in NSCLC patients (2–4). This evidence concerns the gene EGFR and non-small cell lung carcinoma.